Rheumatology

Macrophage activation syndrome

Questions discussed in this category

How would you approach escalation of therapy in an adult patient with refractory Still’s disease and associated MAS/HLH (ferritin >100,000, transaminitis, DIC) despite high-dose steroids, high-dose anakinra, tocilizumab, and ruxolitinib?

Subsequently, emapalumab was initiated with a loading dose, followed by etoposide, which led to improvement in both symptoms and laboratory values. I...

1 Answer available

When would you consider use of emapalumab for HLH/MAS ?

1 Answer available

Would you consider combination belimumab and anakinra for a patient who has SLE and MAS?

MAS has responded to anakinra in the past.

2 Answers available

How do you approach management of a patient with persistent EBV infection and MAS despite treatment with Rituximab, anakinra and canakinumab?

Would you consider alternative B cell depleting therapies such as ofatumumab or ocrelizumab?

1 Answer available

What is the difference between Multisystem Inflammatory Syndrome in Adults (MIS-A) and MAS/HLH?

1 Answer available

Do you recommend using IL-1/IL-6 inhibitors in COVID-19 multisystem inflammatory syndrome in adults (MIS-A)?

1 Answer available

Papers discussed in this category

ACR Open Rheumatol, 2021 Aug 25

Performance of Cytokine Storm Syndrome Scoring Systems in Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children.

Annals of the rheumatic diseases, 2023 Jul 24

The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS).

Rheumatology

Macrophage activation syndrome

Questions discussed in this category

Papers discussed in this category

Related Topics in Rheumatology